17720-12-6

Basic information

• Product Name: D-Histidine methyl ester
• Synonyms: D-Histidine methyl ester
• CAS NO: 17720-12-6
• Molecular Formula: C₇H₁₁N₃O₂
• Molecular Weight: 169.18114
• Mol File: 17720-12-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: D-Histidine methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: D-Histidine methyl ester(17720-12-6)
• EPA Substance Registry System: D-Histidine methyl ester(17720-12-6)

Safety Data

• Hazardous Substances Data: 17720-12-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
D-Histidine methyl ester is used as an intermediate in the synthesis of N-[3-(N-L-Alanyl)-amino-3-carboxypropyl]-D-histidine Trihydrochloride (A510975), which is an analog of Nicotianamine (N408500). Nicotianamine is a phytosiderophore produced in higher plants, consisting of iron chelating amino acids that promote the uptake of iron from the soil. The synthesized compound A510975 may have potential applications in the development of drugs targeting iron-related disorders or in the treatment of diseases where iron homeostasis is disrupted.
Additionally, D-Histidine methyl ester can be utilized in the development of other pharmaceutical compounds, such as peptidomimetics, which are synthetic molecules that mimic the structure and function of natural peptides. These peptidomimetics can be used as therapeutic agents, targeting various biological processes and pathways.
Used in Biotechnology Applications:
In the biotechnology industry, D-Histidine methyl ester can be employed in the synthesis of novel bioactive peptides or proteins with specific functions. These bioactive molecules can be used for various purposes, such as targeting specific receptors, modulating cellular signaling pathways, or acting as enzyme inhibitors. The synthesized peptides or proteins can be applied in drug discovery, diagnostics, and therapeutics.
Furthermore, D-Histidine methyl ester can be used in the development of advanced drug delivery systems, such as nanoparticles or liposomes, to improve the bioavailability, stability, and targeted delivery of therapeutic agents. These drug delivery systems can enhance the efficacy of the synthesized compounds and reduce potential side effects.

Upstream product

• 77714-38-6 3-(1H-Imidazol-4-yl)-2-((E)-3-oxo-propenylamino)-propionic acid methyl ester 
• 77714-39-7 3-(1H-Imidazol-4-yl)-2-((E)-2-methyl-3-oxo-propenylamino)-propionic acid methyl ester 
• 328526-86-9 (R)-histidine monohydrochloride monohydrate 
• 4098-71-9 isophorone diisocyanate 
• 5619-10-3 L-histidine methyl ester dihydrochloride 
• 67-56-1 methanol 
• 6341-24-8 D-histidine monohydrochloride 
• 351-50-8 D-histidin 
• 71-00-1 L-histidine 

Downstream Products

• 6298-09-5 2,4,5-tris-benzoylamino-pent-4-enoic acid methyl ester 
• 1596-64-1 (+/-)-2-amino-3-(1⁽³⁾H-imidazol-4-yl)-propan-1-ol; dihydrochloride 
• 75614-93-6 [3H]-(R)α-methylhistamine 
• 75614-85-6 R-(-)-4-(2-Amino-3-chlorpropyl)-imidazol-dihydrochlorid 
• 351-50-8 D-histidin 
• 1352627-48-5 (R)-methyl 2-(3-(4-(2-((6-amino-9-((2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxytetrahydrofuran-2-yl)-9H-purin-2-yl)amino)ethyl)phenyl)propanamido)-3-(1H-imidazol-4-yl)propanoate 
• 1352627-63-4 (R)-2-(3-(4-(2-((6-amino-9-((2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxytetrahydrofuran-2-yl)-9H-purin-2-yl)amino)ethyl)phenyl)propanamido)-3-(1H-imidazol-4-yl)propanoic acid 
• 55714-15-3 Z(OMe)-Ile-His-OMe 
• 209467-29-8 (S)-2-[(6-{[Benzyloxycarbonyl-(2-benzyloxycarbonylamino-ethyl)-amino]-methyl}-pyridine-2-carbonyl)-amino]-3-(3H-imidazol-4-yl)-propionic acid methyl ester 
• 331262-37-4 2-(3-benzyloxycarbonylamino-4,4,5,5,6,6,7,7,8,8,8-undecafluoro-octanoylamino)-3-(1H-imidazol-4-yl)-propionic acid methyl ester 
• 331262-38-5 2-(3-benzyloxycarbonylamino-4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-pentadecafluoro-decanoylamino)-3-(1H-imidazol-4-yl)-propionic acid methyl ester 
• 78640-70-7 (S)-3-(3H-Imidazol-4-yl)-2-{[1-phenyl-meth-(E)-ylidene]-amino}-propionic acid methyl ester 

Relevant articles and documents

NITROGEN-CONTAINING COMPOUND, METHOD FOR MANUFACTURING THE SAME, AND OPTICAL FUNCTIONAL MATERIAL INCLUDING THE SAME

PROBLEM TO BE SOLVED: To provide a novel nitrogen-containing compound having luminescence property. SOLUTION: A nitrogen-containing compound represented by the following formula (I) in which RA, RB, R1, R2, R3, R4, and X are either one of the following (1) and (2). SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT

NOVEL PYRROLO-LACTONE AND PYRROLE COMPOUNDS INDUCING CELLULAR GLUTATHIONE RECOVERY EFFECT AGAINST REACTIVE OXYGEN SPECIES, AND METHOD FOR PREPARING THE SAME

The present invention provides: a novel pyrrolo-lactone compound, which can be used as an improved pain therapeutic agent containing various substituents by using glucose and ribose as reducing sugars and conducting a reaction with various kinds of natural and unnatural amino acids; and novel pyrrolo compounds produced during a process of manufacturing the same. The novel pyrrolo-lactone and pyrrole compounds are substances which can be used as improved pain therapeutic agent by having increased restoration ability of glutathione in living cells against reactive oxygen species.COPYRIGHT KIPO 2019

Histidine–dialkoxyanthracene dyad for selective and sensitive detection of mercury ions

Histidine-dialkoxyanthracene (HDA) was synthesised as a turn off type fluorescent sensor for fast and sensitive detection of mercury ions (Hg2+) in aqueous media. The two histidine moieties act as ‘claws’ to selectively complex Hg2+. The binding ratio of HDA to Hg2+ was 1:1 (metal-to-ligand ratio). The association constant for Hg2+ towards the receptor HDA obtained from Benesi–Hildebrand plot was found to be 3.22?×?104?M?1 with detection limit as low as 4.7?nM (0.94?μg/L).

Exciton-Coupled Circular Dichroism Characterization of Monotopically Binding Guests in Host?Guest Complexes with a Bis(zinc porphyrin) Tweezer

A stiff-stilbene-linked bisporphyrin tweezer with inherent helicity was used for exciton-coupled circular dichroism (ECCD) characterization of a series of monotopically binding amine guest molecules. CD signals were observed for a variety of monoamines at relatively low tweezer/amine (host/guest) ratios between 1 : 10 to 1 : 70. For the amines producing the most intense CD signals, a binding stoichiometry of 1 : 2 was found. A likely explanation is the presence of guest-guest interactions in the complexes. This is supported by the correlation observed between CD signal intensity and magnitude of possible noncovalent binding between the guests, which can be divided into three groups showing no, moderate and strong response, respectively. Further support for this rationalization comes from molecular modelling.

SILOXANE POLYMERS WITH A CENTRAL POLYSILOXANE POLYMER BLOCK WITH TERMINAL ORGANOFUNCTIONAL RADICALS COMPRISING UREA AND/OR CARBAMATE GROUPS AND AMINO ACID RADICALS

The invention relates to siloxane polymer comprising a central polysiloxane polymer block B with organofunctional radicals, which are terminal or bonded laterally on the polymer block, comprising IPDI and amino acid derivatives which are covalently bonded via a hydrophobic or hydrophilic linker group Q1′, Q2′, and to compositions comprising these siloxanes. Furthermore, processes for their preparation and their use are disclosed.

Structure-stability correlations for imine formation in aqueous solution

Imine formation between 25 aldehydes and 13 amines in aqueous solution in the pH range 7-11 was studied by 1H NMR spectroscopy. A three-parameter linear equation correlating logarithms of imine formation constants with pKa and HOMO energies of amines and LUMO energies of aldehydes is proposed. In view of the widespread occurrence of imine-forming processes in both chemistry and biology, the data presented are of significance for physical organic chemistry and of particular interest for dynamic combinatorial chemistry. Copyright

Five-membered ring systems with bonded imidazolyl ring substituents

A class of 5-membered heterocyclic compounds having at least one heteroatom, substituted on the heterocyclic ring by an imidazolyl moiety, are useful in the treatment of psychotic disorders (e.g. schizophrenia and mania); anxiety; alcohol or drug withdrawal or dependence; pain; gastric stasis; gastric dysfunction (such as occurs with dyspepsia, peptic ulcer, reflux oesophagitis and flatulence); migraine, nausea and vomiting; movement disorders; and presenile and senile dementia.

4,5,6,7-TETRAHYDRO-1H-IMIDAZO(4,5-C)PYRIDINE-6-CARBOXYLIC ACID ANALOGS HAVING ANTIHYPERTENSIVE ACTIVITY

This invention relates to novel substituted derivatives of 4,5, 6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid and analogs thereof, which are useful for the treatment of hypertension, as well as, novel pharmaceutical compositions and methods of use.